You're ignoring the regulation in S87 that stipulates DECENTRALIZED mfg... which will facilitate a franchise business model to provide DCVax therapy near patients.
S87 does not stipulate it. It eases the regulatory burden for any use of a decentralized mfg process. That is all.
It does not change the obvious fact that POS mfg for -L would be VERY expensive for no gain.
It is absolutely impossible for any rational person not to see why the concept is a non-starter.